1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. RemeGen Co., Ltd.
  6. News
  7. Summary
    9995   CNE1000048G6

REMEGEN CO., LTD.

(9995)
  Report
Delayed Hong Kong Stock Exchange  -  03:21 2022-07-05 am EDT
50.40 HKD   -0.59%
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Director
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about REMEGEN CO., LTD.
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Dire..
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/12RemeGen Co., Ltd. Announces Executive Changes
CI
04/11UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108
MT
03/31RemeGen Lists in Shanghai's STAR Market
MT
03/22RemeGen Prices Shanghai IPO to Raise $410 Million
MT
02/20RemeGen Turns to Profit in 2021 on Launch of Core Autoimmune, Cancer Drugs; Shares Rise..
MT
02/20RemeGen Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 20..
CI
01/25Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of ..
CI
01/24RemeGen Completes Phase 2 Trial of Sjögren's Syndrome Treatment in China
MT
01/24RemeGen Co., Ltd. Completes the Phase II Clinical Study for Telitacicept to Treat Patie..
CI
01/12Chinese Regulator Approves RemeGen's Shanghai IPO Application; Shares Jump 9%
MT
01/05Chinese Regulators Grant Conditional Marketing Approval to Remegen's Urothelial Carcino..
MT
01/05RemeGen Co., Ltd. Announces National Medical Products Administration Grants Conditional..
CI
More most relevant news
All news about REMEGEN CO., LTD.
05/05RemeGen Co., Ltd. Approves Appointment of Chen Yunjin as Independent Non-Executive Dire..
CI
04/28RemeGen Widens Q1 Loss as R&D, Selling Expenses Balloon
MT
04/27RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/12RemeGen Co., Ltd. Announces Executive Changes
CI
04/11UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108
MT
03/31RemeGen Lists in Shanghai's STAR Market
MT
03/22RemeGen Prices Shanghai IPO to Raise $410 Million
MT
02/20RemeGen Turns to Profit in 2021 on Launch of Core Autoimmune, Cancer Drugs; Shares Rise..
MT
02/20RemeGen Co., Ltd. Reports Earnings Results for the Fourth Quarter Ended December 31, 20..
CI
01/25Remegen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of ..
CI
More news
News in other languages on REMEGEN CO., LTD.
05/05RemeGen Co., Ltd. approuve la nomination de Chen Yunjin en tant que directeur non exécu..
04/28RemeGen creuse sa perte au 1er trimestre en raison de l'augmentation des frais de R&D e..
04/27RemeGen Co., Ltd. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/12RemeGen Co., Ltd. annonce des changements de direction
02/20RemeGen réalise des bénéfices en 2021 grâce au lancement de médicaments de base contre ..
02/20RemeGen Co., Ltd. annonce ses résultats pour le quatrième trimestre et l'année complète..
01/25Le telitacicept de Remegen obtient des résultats positifs dans un essai de phase II pou..
01/24RemeGen Co., Ltd. achève l'étude clinique de phase II sur le telitacicept pour le trait..
01/12Les actions de Hong Kong atteignent leur plus haut niveau depuis sept semaines ; RemeGe..
01/12L'autorité de réglementation chinoise approuve la demande d'introduction en bourse de R..
More news
Analyst Recommendations on REMEGEN CO., LTD.
04/11UBS Upgrades RemeGen to Buy From Neutral, Adjusts Price Target to HK$75.03 From HK$108
MT
More recommendations
Press releases
2021REMEGEN : Announcement regarding h share full circulation listing approval granted by the ..
PU
2021REMEGEN : (1) proposed issue of a shares and listing on the sci-tech board and other ancil..
PU
2021REMEGEN : Notice of the 2021 first class meeting of h shareholders
PU
2021REMEGEN : Proxy form for use at the 2021 first class meeting of h shareholders
PU
2021REMEGEN : Proxy form for use at the 2021 first class meeting of domestic shareholders and ..
PU
More press releases